SCHEMBL25246761

SCHEMBL25246761

O=Cc1cnc2cc(F)ccn12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.38
WDR77 Q9BQA1 1/20 0.38
FLT3 P36888 5/20 0.37
CYP11B1 P15538 2/20 0.36
CYP11B2 P19099 2/20 0.36
KDR P35968 2/20 0.33
ALDH1A1 P00352 5/20 0.32
KDM4E B2RXH2 2/20 0.32
GAA P10253 1/20 0.32
PKM P14618 1/20 0.32
MGLL Q99685 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
DYRK1A Q13627 1/20 0.31
DYRK2 Q92630 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
PIK3CA P42336 1/20 0.31
FGFR3 P22607 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5634440 0.79 ALDH1A1 (0.51) PRMT5WDR77FLT3CYP11B1CYP11B2
SCHEMBL20049151 0.79 ALDH1A1 (0.41) KDRALDH1A1KDM4EGAAPKM
SCHEMBL31174787 0.79 ALDH1A1 (0.38) FLT3ALDH1A1KDM4EMGLLDYRK1A
SCHEMBL4803489 0.76 FLT3 (0.41) PRMT5WDR77FLT3ALDH1A1KDM4E
SCHEMBL20844771 0.76 PRMT5 (0.41) PRMT5WDR77FLT3CYP11B1CYP11B2
SCHEMBL5251357 0.76 KDR (0.62) FLT3KDR
SCHEMBL12779970 0.74 KDR (0.57) FLT3KDRPIK3CAFGFR3
SCHEMBL3787763 0.74 ADORA2A (0.40) PRMT5WDR77FLT3CYP11B1CYP11B2
SCHEMBL21591164 0.73 FLT3 (0.40) PRMT5WDR77FLT3CYP11B1CYP11B2
SCHEMBL21863396 0.73 CYP11B1 (0.45) PRMT5WDR77FLT3CYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
US-20250059184-A1 IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. 2025-02-20 US disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
US-11820766-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-11-21 US disclosed
US-20230242531-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-08-03 US disclosed
WO-2023114844-A1 IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF DELIX THERAPEUTICS, INC. (US) 2023-06-22 WO disclosed
US-20230145249-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2023-05-11 US disclosed
US-20220332713-A1 Monoacylglycerol Lipase Modulators JANSSEN PHARMACEUTICA NV (BE) 2022-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332713-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PRMT5 3181/4885WDR77 2088/4885FLT3 2356/4885
US-20230242531-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PRMT5 3303/4885WDR77 2135/4885FLT3 2455/4885
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH PRMT5 4530/4885WDR77 2974/4885FLT3 4050/4885
US-20230145249-A1 Monoacylglycerol Lipase Modulators MGLL, LPL, PNLIP PRMT5 3181/4885WDR77 2088/4885FLT3 2356/4885
US-20250059184-A1 IMIDAZOPYRIDINE PSYCHOPLASTOGENS AND USES THEREOF GRIN2A, GAP43, GRIN2C PRMT5 1087/4885WDR77 1748/4885FLT3 3395/4885
US-11820766-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP PRMT5 3181/4885WDR77 2088/4885FLT3 2356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.